PEN Quote, Financials, Valuation and Earnings

ICU Medical has a net margin of 12.1% compared to Penumbra's net margin of -2.56%. Penumbra's return on equity of 3.62% beat ICU Medical's return on equity of -4.64%.

Penumbra has a consensus price target of $313.81, signalling upside risk potential of 33.87%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 49.16%. Given that ICU Medical has higher upside potential than Penumbra, analysts believe ICU Medical is more attractive than Penumbra.

Penumbra has a beta of 0.473, which suggesting that the stock is 52.734% less volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 13.002%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than ICU Medical quarterly revenues of $604.7M. Penumbra's net income of $39.2M is higher than ICU Medical's net income of -$15.5M. Notably, Penumbra's price-to-earnings ratio is 221.14x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 7.47x versus 1.26x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 12.1% compared to Penumbra's net margin of 30.99%. Penumbra's return on equity of 3.62% beat Intuitive Surgical's return on equity of 15.82%.

Penumbra has a consensus price target of $313.81, signalling upside risk potential of 33.87%. On the other hand Intuitive Surgical has an analysts' consensus of $581.45 which suggests that it could grow by 13.42%. Given that Penumbra has higher upside potential than Intuitive Surgical, analysts believe Penumbra is more attractive than Intuitive Surgical.

Penumbra has a beta of 0.473, which suggesting that the stock is 52.734% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Penumbra's net income of $39.2M is lower than Intuitive Surgical's net income of $698.4M. Notably, Penumbra's price-to-earnings ratio is 221.14x while Intuitive Surgical's PE ratio is 75.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 7.47x versus 21.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 12.1% compared to Penumbra's net margin of -5.14%. Penumbra's return on equity of 3.62% beat Integer Holdings's return on equity of 4.85%.

Penumbra has a consensus price target of $313.81, signalling upside risk potential of 33.87%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 27%. Given that Penumbra has higher upside potential than Integer Holdings, analysts believe Penumbra is more attractive than Integer Holdings.

Penumbra has a beta of 0.473, which suggesting that the stock is 52.734% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Integer Holdings quarterly revenues of $437.4M. Penumbra's net income of $39.2M is higher than Integer Holdings's net income of -$22.5M. Notably, Penumbra's price-to-earnings ratio is 221.14x while Integer Holdings's PE ratio is 55.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 7.47x versus 2.36x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 12.1% compared to Penumbra's net margin of 8.48%. Penumbra's return on equity of 3.62% beat Merit Medical Systems's return on equity of 9.19%.

Penumbra has a consensus price target of $313.81, signalling upside risk potential of 33.87%. On the other hand Merit Medical Systems has an analysts' consensus of $108.73 which suggests that it could grow by 29.51%. Given that Penumbra has higher upside potential than Merit Medical Systems, analysts believe Penumbra is more attractive than Merit Medical Systems.

Penumbra has a beta of 0.473, which suggesting that the stock is 52.734% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.358%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Merit Medical Systems quarterly revenues of $355.4M. Penumbra's net income of $39.2M is higher than Merit Medical Systems's net income of $30.1M. Notably, Penumbra's price-to-earnings ratio is 221.14x while Merit Medical Systems's PE ratio is 41.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 7.47x versus 3.63x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.